AAAAAA

   
Results: 1-15 |
Results: 15
Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption
Authors: Violette, SM Guan, W Bartlett, C Smith, JA Bardelay, C Antoine, E Rickles, RJ Mandine, E Van Schravendijk, MR Adams, SE Lynch, BA Shakespeare, WC Yang, M Jacobsen, VA Takeuchi, CS Macek, KJ Bohacek, RS Dalgarno, DC Weigele, M Lesuisse, D Sawyer, TK Baron, R
Citation: Sm. Violette et al., Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption, BONE, 28(1), 2001, pp. 54-64
Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide
Authors: Shahripour, AB Plummer, MS Lunney, EA Sawyer, TK Stankovic, CJ Connolly, MK Rubin, JR Walker, NPC Brady, KD Allen, HJ Talanian, RV Wong, WW Humblet, C
Citation: Ab. Shahripour et al., Structure-based design of caspase-1 inhibitor containing a diphenyl ether sulfonamide, BIOORG MED, 11(20), 2001, pp. 2779-2782
A novel phosphotyrosine mimetic 4 '-carboxymethyloxy-3 '-phosphonophenylalanine (Cpp): Exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain
Authors: Kawahata, N Yang, MG Luke, GP Shakespeare, WC Sundaramoorthi, R Wang, YH Johnson, D Merry, T Violette, S Guan, W Bartlett, C Smith, J Hatada, M Lu, XD Dalgarno, DC Eyermann, CJ Bohacek, RS Sawyer, TK
Citation: N. Kawahata et al., A novel phosphotyrosine mimetic 4 '-carboxymethyloxy-3 '-phosphonophenylalanine (Cpp): Exploitation in the design of nonpeptide inhibitors of pp60(Src) SH2 domain, BIOORG MED, 11(17), 2001, pp. 2319-2323
Drug design - Chemistry and biology
Authors: Sawyer, TK
Citation: Tk. Sawyer, Drug design - Chemistry and biology, BIOTECHNIQU, 31(5), 2001, pp. 1164
Proteomics - Structure and function
Authors: Sawyer, TK
Citation: Tk. Sawyer, Proteomics - Structure and function, BIOTECHNIQU, 31(1), 2001, pp. 156
Deciphering therapeutic targets
Authors: Sawyer, TK
Citation: Tk. Sawyer, Deciphering therapeutic targets, BIOTECHNIQU, 30(5), 2001, pp. 1086
Cancer - Emerging breakthrough drugs
Authors: Sawyer, TK
Citation: Tk. Sawyer, Cancer - Emerging breakthrough drugs, BIOTECHNIQU, 30(3), 2001, pp. 626
Genes to drugs
Authors: Sawyer, TK
Citation: Tk. Sawyer, Genes to drugs, BIOTECHNIQU, 30(1), 2001, pp. 164
X-ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor
Authors: Bohacek, RS Dalgarno, DC Hatada, M Jacobsen, VA Lynch, BA Macek, KJ Merry, T Metcalf, CA Narula, SS Sawyer, TK Shakespeare, WC Violette, SM Weigele, M
Citation: Rs. Bohacek et al., X-ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor, J MED CHEM, 44(5), 2001, pp. 660-663
Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain
Authors: Metcalf, CA Eyermann, CJ Bohacek, RS Haraldson, CA Varkhedkar, VM Lynch, BA Bartlett, C Violette, SM Sawyer, TK
Citation: Ca. Metcalf et al., Structure-based design and solid-phase parallel synthesis of phosphorylated nonpeptides to explore hydrophobic binding at the Src SH2 domain, J COMB CHEM, 2(4), 2000, pp. 305-313
A Src SH2 selective binding compound inhibits osteoclast-mediated resorption
Authors: Violette, SM Shakespeare, WC Bartlett, C Guan, W Smith, JA Rickles, RJ Bohacek, RS Holt, DA Baron, R Sawyer, TK
Citation: Sm. Violette et al., A Src SH2 selective binding compound inhibits osteoclast-mediated resorption, CHEM BIOL, 7(3), 2000, pp. 225-235
Structure-based design of novel bicyclic nonpeptide inhibitors for the SrcSH2 domain
Authors: Shakespeare, WC Bohacek, RS Azimioara, MD Macek, KJ Luke, GP Dalgarno, DC Hatada, MH Lu, XD Violette, SM Bartlett, C Sawyer, TK
Citation: Wc. Shakespeare et al., Structure-based design of novel bicyclic nonpeptide inhibitors for the SrcSH2 domain, J MED CHEM, 43(21), 2000, pp. 3815-3819
Peptidomimetic and nonpeptide drug discovery: Chemical nature and biological targets
Authors: Sawyer, TK
Citation: Tk. Sawyer, Peptidomimetic and nonpeptide drug discovery: Chemical nature and biological targets, DRUG PHARM, 101, 2000, pp. 81-114
Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70
Authors: Vu, CB Corpuz, EG Pradeepan, SG Violette, S Bartlett, C Sawyer, TK
Citation: Cb. Vu et al., Nonpeptidic SH2 inhibitors of the tyrosine kinase ZAP-70, BIOORG MED, 9(20), 1999, pp. 3009-3014
Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70
Authors: Vu, CB Corpuz, EG Merry, TJ Pradeepan, SG Bartlett, C Bohacek, RS Botfield, MC Eyermann, CJ Lynch, BA MacNeil, IA Ram, MK van Schravendijk, MR Violette, S Sawyer, TK
Citation: Cb. Vu et al., Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, J MED CHEM, 42(20), 1999, pp. 4088-4098
Risultati: 1-15 |